MilliporeSigma
All Photos(1)

Documents

Z2001

Sigma-Aldrich

Zonisamide sodium salt

≥98% (HPLC), powder

Sign Into View Organizational & Contract Pricing

Synonym(s):
1,2-Benzisoxazole-3-methanesulfonamide sodium-potassium salt, Aleviatin sodium-potassium salt, Exceglan sodium-potassium salt, Excegram sodium-potassium salt
Empirical Formula (Hill Notation):
C8H7N2NaO3S
CAS Number:
Molecular Weight:
234.21
MDL number:
PubChem Substance ID:
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

H2O: >5 mg/mL

originator

Eisai

SMILES string

[Na]NS(=O)(=O)Cc1noc2ccccc12

InChI

1S/C8H7N2O3S.Na/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7;/h1-4H,5H2,(H-,9,11,12);/q-1;+1

InChI key

ZVBIRPKGWOVBLG-UHFFFAOYSA-N

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
H8759209104ED2P
Zonisamide sodium salt ≥98% (HPLC), powder

Sigma-Aldrich

Z2001

Zonisamide sodium salt

form

powder

form

powder

form

powder

form

powder

color

white to beige

color

off-white

color

-

color

-

solubility

H2O: >5 mg/mL

solubility

H2O: 50 mg/mL

solubility

-

solubility

3 M KOH: 160 mg/mL, clear to very slightly hazy, colorless to faintly yellow

originator

Eisai

originator

-

originator

-

originator

-

Quality Level

100

Quality Level

200

Quality Level

200

Quality Level

200

Biochem/physiol Actions

Zonisamide sodium salt is an anti-epileptic. It is effective in various animal epilepsy models and humans with both partial and generalized epileptic seizures. Zonisamide sodium salt also scavenges nitric oxide (NO).

Features and Benefits

This compound was developed by Eisai. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

Product numbers are combined with Pack Sizes/Quantity when displayed on the website (example: T1503-25G). Please make sure you enter ONLY the product number in the Product Number field (example: T1503).

Example:

T1503
Product Number
-
25G
Pack Size/Quantity

Additional examples:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

enter as 1.000309185)

Having trouble? Feel free to contact Technical Service for assistance.

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich Products

  • For a lot number such as TO09019TO, enter it as 09019TO (without the first two letters 'TO').

  • For a lot number with a filling-code such as 05427ES-021, enter it as 05427ES (without the filling-code '-021').

  • For a lot number with a filling-code such as STBB0728K9, enter it as STBB0728 without the filling-code 'K9'.

Not Finding What You Are Looking For?

In some cases, a COA may not be available online. If your search was unable to find the COA you can request one.

Request COA

Customers Also Viewed

Slide 1 of 8

1 of 8

Lacosamide solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-029

Lacosamide solution

vibrant-m

Y0001982

Lacosamide

Sigma-Aldrich

Sigma-Aldrich

SML0936

Teriflunomide

(±)-Vigabatrin

Sigma-Aldrich

V8261

(±)-Vigabatrin

Dong Wook Kim et al.
Epilepsy & behavior : E&B, 23(4), 497-499 (2012-03-24)
Because iatrogenic obesity may hinder medication compliance, it would be a reasonable approach to consider antiepileptic drugs (AEDs) that promote weight loss in overweight patients. We performed an open-label, observational study to assess the effects of zonisamide on weight in
Kouji Fukuyama et al.
Pharmaceuticals (Basel, Switzerland), 13(5) (2020-05-24)
To understand the pathomechanism and pathophysiology of autosomal dominant sleep-related hypermotor epilepsy (ADSHE), we studied functional abnormalities of glutamatergic transmission in thalamocortical pathway from reticular thalamic nucleus (RTN), mediodorsal thalamic nucleus (MDTN) to orbitofrontal cortex (OFC) associated with S286L-mutant α4β2-nicotinic
Vedat Ali Yürekli et al.
Cellular and molecular neurobiology, 33(2), 205-212 (2012-12-12)
Parkinson's disease is an incurable progressive neurological condition caused by a degeneration of dopamine-producing cells characterized by motor and non-motor symptoms. The major mechanisms of the antiepileptic actions of ZNS are inhibition of voltage-gated Na(+) channel, T-type voltage-sensitive Ca(2+) channel
Susan L McElroy et al.
Journal of clinical psychopharmacology, 32(2), 165-172 (2012-03-01)
Weight gain is commonly observed with olanzapine treatment. Zonisamide is an antiepileptic drug associated with weight loss. This study examined the effectiveness of zonisamide in preventing weight gain in 42 patients beginning olanzapine for bipolar disorder or schizophrenia. Each patient
Kouji Fukuyama et al.
Pharmaceuticals (Basel, Switzerland), 13(6) (2020-06-11)
Recent studies using the genetic partial epilepsy model have demonstrated that hyperfunction of astroglial hemichannels contributes to pathomechanism of epileptic seizure. Therefore, to explore the novel anticonvulsive mechanisms, the present study determined the effects of voltage-dependent Na+ channel (VDSC)-inhibiting anticonvulsants

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service